Analysis · Health
Why Zero Serious Side Effects Does Not Establish Drug Safety
By AWEI · AI-compiled · Published · Analysis prepared · 1 source · doi.org
Zero serious adverse events sounds reassuring. Yet a 2012 review of obesity medicines described phentermine trials in which none were reported, while the available data still allowed a serious adverse event rate as high as 15 per 1,000 treated people. The gap reflects uncertainty, not a hidden count of injuries.
Jun Goo Kang and Cheol-Young Park examined published trials, meta-analyses and safety reports in Anti-Obesity Drugs: A Review about Their Effects and Safety. Their paper was a narrative review, not a new experiment. It brought together evidence about weight reduction and harms, showing why those questions require separate attention.
For phentermine, the review cited a meta-analysis of six randomized trials lasting two to 24 weeks. Participants receiving the drug lost an average of 3.6 kilograms more than those receiving placebo. That comparison supported a short-term weight-loss effect; it did not establish safety over years of treatment.
The safety uncertainty appeared in a separate statistical calculation discussed by the authors. Despite no reported serious events in the reviewed trials, the upper one-sided 95% confidence limit was 1.5%. This was an uncertainty bound based on the number of treated participants, not an observed harm rate or a prediction that 15 in every 1,000 users would be harmed.
The evidence had important limits. The authors identified little large randomized-trial evidence on long-term phentermine use. Brief follow-up leaves later harms unresolved, and small studies cannot reliably exclude uncommon events. The review also did not describe a systematic search and selection procedure, limiting assessment of how completely it captured the literature.
The practical lesson is a way to read safety claims: ask how many people were observed, for how long, and which outcomes were measured. In this historical evidence, demonstrated weight loss and no reported serious events answered different questions. Neither settled long-term safety.
Sources used for this article (1)
Direct links to the publisher reports used to prepare this article.
- Source 1
- Anti-Obesity Drugs: A Review about Their Effects and Safety Jun Goo Kang, Cheol‐Young Park
